98 related articles for article (PubMed ID: 26940138)
1. GZD856, a novel potent PDGFRα/β inhibitor, suppresses the growth and migration of lung cancer cells in vitro and in vivo.
Zhang Z; Ren X; Lu X; Wang D; Hu X; Zheng Y; Song L; Pang H; Yu R; Ding K
Cancer Lett; 2016 May; 375(1):172-178. PubMed ID: 26940138
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of platelet-derived growth factor receptor α by MEDI-575 reduces tumor growth and stromal fibroblast content in a model of non-small cell lung cancer.
Laing N; McDermott B; Wen S; Yang D; Lawson D; Collins M; Reimer C; Hall PA; Andersén H; Snaith M; Wang X; Bedian V; Cao ZA; Blakey D
Mol Pharmacol; 2013 Jun; 83(6):1247-56. PubMed ID: 23558446
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451.
Roberts WG; Whalen PM; Soderstrom E; Moraski G; Lyssikatos JP; Wang HF; Cooper B; Baker DA; Savage D; Dalvie D; Atherton JA; Ralston S; Szewc R; Kath JC; Lin J; Soderstrom C; Tkalcevic G; Cohen BD; Pollack V; Barth W; Hungerford W; Ung E
Cancer Res; 2005 Feb; 65(3):957-66. PubMed ID: 15705896
[TBL] [Abstract][Full Text] [Related]
4. Stromal platelet-derived growth factor receptor α (PDGFRα) provides a therapeutic target independent of tumor cell PDGFRα expression in lung cancer xenografts.
Gerber DE; Gupta P; Dellinger MT; Toombs JE; Peyton M; Duignan I; Malaby J; Bailey T; Burns C; Brekken RA; Loizos N
Mol Cancer Ther; 2012 Nov; 11(11):2473-82. PubMed ID: 22933705
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia.
Wang Q; Liu F; Qi S; Qi Z; Yan XE; Wang B; Wang A; Wang W; Chen C; Liu X; Jiang Z; Hu Z; Wang L; Wang W; Ren T; Zhang S; Yun CH; Liu Q; Liu J
Eur J Med Chem; 2018 Apr; 150():366-384. PubMed ID: 29544149
[TBL] [Abstract][Full Text] [Related]
6. Combined anti-PDGFRalpha and PDGFRbeta targeting in non-small cell lung cancer.
Reinmuth N; Liersch R; Raedel M; Fehrmann F; Fehrmann N; Bayer M; Schwoeppe C; Kessler T; Berdel W; Thomas M; Mesters RM
Int J Cancer; 2009 Apr; 124(7):1535-44. PubMed ID: 19115205
[TBL] [Abstract][Full Text] [Related]
7. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
Zhang J; Zhang L; Su X; Li M; Xie L; Malchers F; Fan S; Yin X; Xu Y; Liu K; Dong Z; Zhu G; Qian Z; Tang L; Schöttle J; Zhan P; Ji Q; Kilgour E; Smith PD; Brooks AN; Thomas RK; Gavine PR
Clin Cancer Res; 2012 Dec; 18(24):6658-67. PubMed ID: 23082000
[TBL] [Abstract][Full Text] [Related]
8. PDGFRalpha/beta expression correlates with the metastatic behavior of human colorectal cancer: a possible rationale for a molecular targeting strategy.
Wehler TC; Frerichs K; Graf C; Drescher D; Schimanski K; Biesterfeld S; Berger MR; Kanzler S; Junginger T; Galle PR; Moehler M; Gockel I; Schimanski CC
Oncol Rep; 2008 Mar; 19(3):697-704. PubMed ID: 18288404
[TBL] [Abstract][Full Text] [Related]
9. Imatinib mesylate inhibits androgen-independent PC-3 cell viability, proliferation, migration, and tumor growth by targeting platelet-derived growth factor receptor-α.
Nayeem MJ; Yamamura A; Hayashi H; Muramatsu H; Nakamura K; Sassa N; Sato M
Life Sci; 2022 Jan; 288():120171. PubMed ID: 34822800
[TBL] [Abstract][Full Text] [Related]
10. Imatinib as a key inhibitor of the platelet-derived growth factor receptor mediated expression of cell surface heparan sulfate proteoglycans and functional properties of breast cancer cells.
Malavaki CJ; Roussidis AE; Gialeli C; Kletsas D; Tsegenidis T; Theocharis AD; Tzanakakis GN; Karamanos NK
FEBS J; 2013 May; 280(10):2477-89. PubMed ID: 23374223
[TBL] [Abstract][Full Text] [Related]
11. Biologic effects of platelet-derived growth factor receptor α blockade in uterine cancer.
Roh JW; Huang J; Hu W; Yang X; Jennings NB; Sehgal V; Sohn BH; Han HD; Lee SJ; Thanapprapasr D; Bottsford-Miller J; Zand B; Dalton HJ; Previs RA; Davis AN; Matsuo K; Lee JS; Ram P; Coleman RL; Sood AK
Clin Cancer Res; 2014 May; 20(10):2740-50. PubMed ID: 24634380
[TBL] [Abstract][Full Text] [Related]
12. Protein kinase A-dependent phosphorylation of Dock180 at serine residue 1250 is important for glioma growth and invasion stimulated by platelet derived-growth factor receptor α.
Feng H; Li Y; Yin Y; Zhang W; Hou Y; Zhang L; Li Z; Xie B; Gao WQ; Sarkaria JN; Raizer JJ; James CD; Parsa AT; Hu B; Cheng SY
Neuro Oncol; 2015 Jun; 17(6):832-42. PubMed ID: 25468898
[TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
McGary EC; Onn A; Mills L; Heimberger A; Eton O; Thomas GW; Shtivelband M; Bar-Eli M
J Invest Dermatol; 2004 Feb; 122(2):400-5. PubMed ID: 15009722
[TBL] [Abstract][Full Text] [Related]
14. Pifithrin-μ is efficacious against non-small cell lung cancer via inhibition of heat shock protein 70.
Zhou Y; Ma J; Zhang J; He L; Gong J; Long C
Oncol Rep; 2017 Jan; 37(1):313-322. PubMed ID: 28004121
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice.
Lev DC; Kim SJ; Onn A; Stone V; Nam DH; Yazici S; Fidler IJ; Price JE
Clin Cancer Res; 2005 Jan; 11(1):306-14. PubMed ID: 15671560
[TBL] [Abstract][Full Text] [Related]
16. Angelicin inhibits human lung carcinoma A549 cell growth and migration through regulating JNK and ERK pathways.
Li G; He Y; Yao J; Huang C; Song X; Deng Y; Xie S; Ren J; Jin M; Liu H
Oncol Rep; 2016 Dec; 36(6):3504-3512. PubMed ID: 27748898
[TBL] [Abstract][Full Text] [Related]
17. PDGFRα and β play critical roles in mediating Foxq1-driven breast cancer stemness and chemoresistance.
Meng F; Speyer CL; Zhang B; Zhao Y; Chen W; Gorski DH; Miller FR; Wu G
Cancer Res; 2015 Feb; 75(3):584-93. PubMed ID: 25502837
[TBL] [Abstract][Full Text] [Related]
18. Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro.
Zhang P; Gao WY; Turner S; Ducatman BS
Mol Cancer; 2003 Jan; 2():1. PubMed ID: 12537587
[TBL] [Abstract][Full Text] [Related]
19. In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy.
Decaudin D; de Cremoux P; Sastre X; Judde JG; Nemati F; Tran-Perennou C; Fréneaux P; Livartowski A; Pouillart P; Poupon MF
Int J Cancer; 2005 Feb; 113(5):849-56. PubMed ID: 15499612
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells.
Shen Y; Ren X; Ding K; Zhang Z; Wang D; Pan J
Oncotarget; 2014 Nov; 5(21):10407-20. PubMed ID: 25431951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
